ASCO 2022: Preclinical Activity of Irreversible Menin Inhibitor, BMF-219, in Chronic Lymphocytic Leukemia
What follows is our patient-friendly summary of this research.: BMF-219, an irreversible menin inhibitor that demonstrated strong preclinical activity against chronic lymphocytic leukemia or CLL patients’ specimens, including those with high-risk markers.